X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million
Deal Type: Acquisition June 28, 2023
Details:
The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million
Deal Type: Acquisition April 18, 2023
Details:
BLU-5937 (camlipixant) is an investigational P2X3 antagonist, for the treatment of refractory chronic cough. Clinical evidence have linked the P2X3 receptor and refractory chronic cough to a sensory nerve dysfunction that can lead to cough hypersensitivity.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
The company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the Supplement (as defined below).
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 18, 2022
Details:
The Company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the supplement.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 14, 2022
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics, for the treatment of refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Phase 2b SOOTHE trial which highlight BLU-5937 was well-tolerated with a low rate of taste-related adverse events (?6.5%) treatment emergent adverse event profile comparable to placebo used for the treatment of refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
